CADTH is committed to supporting Canada’s health care decision-makers through this challenging and uncertain time.
For evidence, tools, and resources related to COVID-19, visit our COVID-19 Evidence Portal.


Begin main content

certolizumab pegol

Last Updated: June 17, 2020
Result type: Reports
Project Number: SR0587-000
Product Line: Reimbursement Review

Generic Name: certolizumab pegol

Brand Name: Cimzia

Manufacturer: UCB Canada Inc.

Therapeutic Area: Psoriasis, moderate to severe plaque

Indications: Psoriasis, moderate to severe plaque

Manufacturer Requested Reimbursement Criteria1: For the treatment of adult patients with moderate to severe plaque psoriasis who are candidates for systemic therapy.

Submission Type: Initial

Project Status: Complete

Biosimilar: No

Date Recommendation Issued: November 20, 2019

Recommendation Type: Reimburse with clinical criteria and/or conditions

Fee Schedule: Schedule A

  1. The requested reimbursement criteria are provided by the applicant and do not necessarily reflect the views of CADTH. Reimbursement criteria from CADTH will be documented in the final recommendation, if applicable.

Key Milestones2

Call for patient input postedOctober 15, 2018
Patient group input closedDecember 03, 2018

- Patient input submission received from the Canadian Association of Psoriasis Patients (CAPP), the Canadian Psoriasis Network (CPN), the Canadian Skin Patient Alliance (CSPA), and Psoriasis Society of Canada

Patient input summary sent for review to patient input groupsJune 13, 2019
Patient group comments on input summary closedJune 20, 2019

- Patient input summary feedback received

Submission receivedMay 13, 2019
Submission acceptedMay 28, 2019
Review initiatedMay 29, 2019
Draft CADTH review report(s) sent to sponsorAugust 23, 2019
Comments from sponsor on draft CADTH review report(s) receivedSeptember 04, 2019
CADTH review team's comments on draft CADTH review report(s) sent to sponsorOctober 03, 2019
Canadian Drug Expert Committee (CDEC) meetingOctober 16, 2019
CDEC recommendation sent to sponsor and drug plansOctober 30, 2019
Embargo period endedNovember 13, 2019
CDEC Final Recommendation & CADTH review report(s) issued to sponsor and drug plansNovember 20, 2019
CDEC Final Recommendation postedNovember 22, 2019
Redaction requests from sponsor on draft CADTH review report(s) receivedDecember 11, 2019
Redacted CADTH review report(s) sent to sponsor and drug plansDecember 23, 2019
Validation of redacted CADTH review report(s) receivedJanuary 07, 2020
Final CADTH review report(s) postedJanuary 29, 2020